Connect Biopharma Holdings Ltd (CNTB) Financial

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The company is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. Its second product candidate, icanbelimod, is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). Icanbelimod is an orally available, small molecule modulator of S1P1 that is designed to reduce inflammation without killing T cells.